Metastatic Triple Negative Breast Cancer clinical trials

Explore recruiting metastatic triple negative breast cancer clinical trials.

Recruiting metastatic triple negative breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Triple Negative Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Treatment of advanced or metastatic triple negative breast cancer with tumor infiltrating lymphocytes (TILs).

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast Cancer

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

An open-label, multicentric, phase 1 study to evaluate the safety, tolerability, and radiation dosimetry of endogenous radioligand therapy with (¹⁷⁷Lu)Lutetiumvipivotidtetraxetan in women with metastatic triple negative breast cancer (TNBC)

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

"TOPOLOGY" : A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

ProspectivE phase 0 pilot study, assessing potential prognostic and theranostic interest of 68Ga-PentiXafor PET-CT In metastatic triple neGative brEast caNCer patiEnts (EXIGENCE)

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negative metastatic triple-negative breast cancer

Spain, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Metastatic Triple Negative Breast Cancer trials by city

Metastatic Triple Negative Breast Cancer in Toronto Metastatic Triple Negative Breast Cancer in Vancouver Metastatic Triple Negative Breast Cancer in Montreal Metastatic Triple Negative Breast Cancer in Calgary Metastatic Triple Negative Breast Cancer in Edmonton Metastatic Triple Negative Breast Cancer in Ottawa Metastatic Triple Negative Breast Cancer in Winnipeg Metastatic Triple Negative Breast Cancer in Quebec City Metastatic Triple Negative Breast Cancer in Hamilton Metastatic Triple Negative Breast Cancer in Kitchener Metastatic Triple Negative Breast Cancer in London Metastatic Triple Negative Breast Cancer in Halifax Metastatic Triple Negative Breast Cancer in New York Metastatic Triple Negative Breast Cancer in Los Angeles Metastatic Triple Negative Breast Cancer in Chicago Metastatic Triple Negative Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease